Drug Profile
Research programme: dengue fever virus vaccine - GenVec/Naval Medical Research Center
Alternative Names: Dengue fever vaccine - GenVecLatest Information Update: 29 Jun 2017
Price :
$50
*
At a glance
- Originator GenVec; Naval Medical Research Center
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Dengue
Most Recent Events
- 16 Jun 2017 GenVec was acquired by Intrexon Corporation
- 28 Mar 2014 Discontinued for Dengue in USA (Parenteral) before 28 March 2014
- 25 Jan 2011 GenVec establishes CRADA with US Naval Medical Research Center for the development of Dengue fever virus vaccine